IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

Shares of IQVIA Holdings Inc. IQV slipped 1.12% to $199.11 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 ...

Over the past year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a significant stake in the company which ...

Barclays lowered the firm’s price target on Iqvia (IQV) to $235 from $255 and keeps an Overweight rating on the shares. The firm says the life ...

BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia ...

Given forthcoming changes to Medicare Part D plans under the Inflation Reduction Act, CMS should collect and publish ...

Concussions were down 17 percent from 2023 and were the lowest on record since the league started tracking data in 2015.

IQVIA Holdings Inc. closed 22.27% below its 52-week high of $261.73, which the company achieved on March 8th.